JO2017B1 - Pharmaceutical-composition for gastric residence - Google Patents

Pharmaceutical-composition for gastric residence

Info

Publication number
JO2017B1
JO2017B1 JO19982017A JOP19982017A JO2017B1 JO 2017 B1 JO2017 B1 JO 2017B1 JO 19982017 A JO19982017 A JO 19982017A JO P19982017 A JOP19982017 A JO P19982017A JO 2017 B1 JO2017 B1 JO 2017B1
Authority
JO
Jordan
Prior art keywords
gastric residence
pharmaceutical
composition
carbon dioxide
benzamide
Prior art date
Application number
JO19982017A
Other languages
Arabic (ar)
Inventor
جيروم بيسي
Original Assignee
سينثيلابو
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سينثيلابو filed Critical سينثيلابو
Application granted granted Critical
Publication of JO2017B1 publication Critical patent/JO2017B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Pharmaceutical composition for gastric residence, characterized in that it comprises: (a) an active principle consisting of a benzamide or benzamide- salt, (b) a carbon dioxide generator system, and (c) a means allowing the partial retention of the carbon dioxide generated by the said carbon dioxide generator system.
JO19982017A 1997-04-18 1998-04-18 Pharmaceutical-composition for gastric residence JO2017B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9704803A FR2762213B1 (en) 1997-04-18 1997-04-18 PHARMACEUTICAL COMPOSITION WITH GASTRIC RETENTION

Publications (1)

Publication Number Publication Date
JO2017B1 true JO2017B1 (en) 1999-05-15

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
JO19982017A JO2017B1 (en) 1997-04-18 1998-04-18 Pharmaceutical-composition for gastric residence

Country Status (19)

Country Link
EP (1) EP0983065A1 (en)
JP (1) JP2001523241A (en)
KR (1) KR20010006353A (en)
CN (1) CN1252720A (en)
AR (1) AR015586A1 (en)
AU (1) AU737634B2 (en)
CA (1) CA2286081A1 (en)
FR (1) FR2762213B1 (en)
HU (1) HUP0002455A3 (en)
IL (1) IL131995A0 (en)
JO (1) JO2017B1 (en)
MA (1) MA26482A1 (en)
NO (1) NO995039L (en)
NZ (1) NZ500288A (en)
PE (1) PE68199A1 (en)
PL (1) PL336273A1 (en)
TN (1) TNSN98049A1 (en)
WO (1) WO1998047506A1 (en)
ZA (1) ZA983258B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (en) * 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
FR2790388B1 (en) * 1999-03-04 2001-04-13 Synthelabo PHARMACEUTICAL COMPOSITIONS COMPRISING A BENZAMIDE AND AT LEAST ONE ABSORPTION PROMOTER
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
FR2949061B1 (en) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma FLOATING MICROGRANULES
ES2536836T3 (en) * 2012-10-12 2015-05-29 Omya International Ag Formulation of gastro-retentive medication and release systems and their method of preparation using calcium carbonate transformed into functional
BR112020011189A2 (en) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. non-racemic mixtures and uses thereof
KR20200110317A (en) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 Crystal form and method for preparing the same
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
US20220323409A1 (en) * 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (en) * 1978-01-20 1979-08-17 Ile De France NEW DERIVATIVES OF 4-AMINO-5-ALKYLSULFONYL ORTHO-ANISAMIDES, THEIR METHODS OF PREPARATION AND THEIR APPLICATION AS PSYCHOTROPES
FR2554718B1 (en) * 1983-11-14 1986-04-04 Ethypharm Sa NEW ORAL SULPIRIDE FORMS FOR SULPIRIDE
FR2556964A1 (en) * 1983-12-23 1985-06-28 Ile De France NEW GALENIC FORMS OF SULPIRIDE USED ORALALLY
JPS62178518A (en) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk New long-acting sulpiride tablets
JPH0776172B2 (en) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 Matrice locks
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials

Also Published As

Publication number Publication date
TNSN98049A1 (en) 2005-03-15
AU7341698A (en) 1998-11-13
CN1252720A (en) 2000-05-10
FR2762213B1 (en) 1999-05-14
CA2286081A1 (en) 1998-10-29
MA26482A1 (en) 2004-12-20
EP0983065A1 (en) 2000-03-08
IL131995A0 (en) 2001-03-19
HUP0002455A2 (en) 2000-12-28
PL336273A1 (en) 2000-06-19
AU737634B2 (en) 2001-08-23
PE68199A1 (en) 1999-07-15
NO995039D0 (en) 1999-10-15
WO1998047506A1 (en) 1998-10-29
AR015586A1 (en) 2001-05-16
JP2001523241A (en) 2001-11-20
NZ500288A (en) 2001-03-30
FR2762213A1 (en) 1998-10-23
KR20010006353A (en) 2001-01-26
HUP0002455A3 (en) 2001-01-29
ZA983258B (en) 1998-10-19
NO995039L (en) 1999-12-17

Similar Documents

Publication Publication Date Title
GB2282366B (en) Device for delivering an audible message
AP9801392A0 (en) Concentrated antibody preparation.
EP0662935A4 (en) Gas generator.
EP0646354A3 (en) Self contained gas powered surgical apparatus.
ZA987126B (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives.
EP0636617A3 (en) Process for the preparation of N-(2-hydromethyl)-piperazin.
GR3034289T3 (en) Di- and trivalent small molecule selectin inhibitors
EP0659769A3 (en) Agent for promoting the proliferation of bifidobacterium.
JO2017B1 (en) Pharmaceutical-composition for gastric residence
BG103714A (en) Pararacetamol-containing tablet
EP0449787A3 (en) Pharmaceutical, dietetic or veterinary compositions with eumetabolic activity
BG103677A (en) Solid mixtures based on sulphonylcarbamides and adjuvants
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
DK1044064T3 (en) Granule coating device for oral administration
TR200001102T2 (en) Substituted tetrahydropyrimidinene derivatives, their production and uses.
NZ308516A (en) Transdermal therapeutic system (tts) for administering testosterone
EP0607897A3 (en) Hydraulically-damped, active engine support.
ZA966885B (en) Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
EP0646505A3 (en) Gas generating device.
DE3674971D1 (en) P-acylaminobenzamide.
TW348157B (en) Equipment and method to hold and to protect objects
IL116262A0 (en) Processes for preparing ranitidine
AU1287001A (en) Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
EP0640795A3 (en) Combustion apparatus.
MX9802809A (en) Urease for the treatment of helicobacter pylori infections.